On June 1, Sihuan Pharmaceutical, a company listed on the Hong Kong Stock Exchange, announced that Jilin Huisheng Bio-Pharmaceutical Co., Ltd. (hereinafter referred to as Huisheng Bio), a non-wholly-owned subsidiary of the group, has completed 500 million yuan in Series A financing, funded by China Life Health Fund, Tianjin Yuanyi, Tianjin Yuanyi Jimao and Ginkgo Capital jointly invested.
It was originally an ordinary financing news, but what is interesting is that two well-known FA institutions in the industry have issued announcements saying that they have served as the exclusive financial advisor of Huisheng Bio.
An industry insider told every reporter that in theory, only one service can be called an exclusive financial advisor, and those who serve together should be called financial advisors.But in reality, even if some FAs serve together, they will still call themselves exclusive to the outside world. "In the final analysis, it is because the industry is too complicated."
